Special Issue "Fatty Liver Syndrome"

A special issue of Gastroenterology Insights (ISSN 2036-7422). This special issue belongs to the section "Liver".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 4109

Special Issue Editor

Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan
Interests: nonalcoholic steatohepatitis; oxidative stress; hepatic fibrosis; diabetes mellitus; liver cirrhosis; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Fatty liver disease is the most prevalent chronic liver disease worldwide. Fatty liver disease is induced by a variety of factors, such as alcohol intake, obesity, diabetes, hepatic virus C infection, endocrine disorder (growth hormone deficiency, testosterone deficiency, hypothyroidism), operation (pancreatoduodenectomy, ilio-cecal bypass), drugs (tamoxifen, methotrexate, steroids, etc.), and genetic polymorphism (PNPLA3, TM6SF2 etc.). Accumulating evidence has established that PNPLA3 SNP is closely associated with fibrosis progression or HCC development in FLS. The term “nonalcoholic fatty liver disease” (NAFLD) was coined by Schaffner, and has been used for a few decades. We do not know how obese patients that are mild drinkers (210~300 g/wk) showing steatohepatitis should be categorized. Both associated steatohepatitis (BASH) has been suggested in this case. It is time to abandon the term “NAFLD and AFLD”. Therefore, we would like to suggest that fatty liver disease can be called “fatty liver syndrome” (FALIS). This Special Issue welcomes original research and review paper regarding FALIS.

Suggested topics:

  • Mechanisms of insulin resistance and hepatic steatosis/fibrosis;
  • The role of alcohol in FLS;
  • The role of SNPs with disease severity in FLS;
  • The role of microbiota in FLS;
  • Endocrine disorder in FLS;
  • Drug-induced FLS;
  • The role of iron metabolism in FLS;
  • Antifibrotic agents in FLS;
  • How can we stop HCC development in FLS?
  • Mechanisms of cardiac/renal disease and FLS;
  • Treatment strategy or pipelines for FLS;
  • Noninvasive tests (NITs) of hepatic fibrosis in FLS;
  • Liver transplantation for FLS.

You may choose our Joint Special Issue in Life.

Assoc. Prof. Dr. Yoshio Sumida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastroenterology Insights is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


11 pages, 3760 KiB  
Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin
Gastroenterol. Insights 2021, 12(2), 155-165; https://doi.org/10.3390/gastroent12020014 - 01 Apr 2021
Cited by 13 | Viewed by 3277
Non-alcoholic fatty disease (NAFLD) is amongst the leading causes of chronic liver disease worldwide. The prevalence of NAFLD in the Middle East is 32%, similar to that observed worldwide. The clinicians in this region face several challenges in diagnosing and treating patients with [...] Read more.
Non-alcoholic fatty disease (NAFLD) is amongst the leading causes of chronic liver disease worldwide. The prevalence of NAFLD in the Middle East is 32%, similar to that observed worldwide. The clinicians in this region face several challenges in diagnosing and treating patients with NAFLD. Additionally, there are no national or regional guidelines to address the concerns faced with current treatment options. Silymarin, derived from milk thistle, provides a rational and clinically proven approach to hepatoprotection. This article focuses on addressing regional diagnostic challenges and provides clear guidance and potential solutions for the use of Silymarin in the treatment of NAFLD in the Middle East. Both clinical and preclinical studies have highlighted the efficiency of Silymarin in managing NAFLD by reducing liver disease progression and improving patient symptoms and quality of life, alongside being safe and well tolerated. An expert panel of professionals from the Middle East convened to establish a set of regional-specific diagnostics. A consensus was established to aid general physicians to address the diagnostic challenges in the region. In conclusion, Silymarin can be considered beneficial in treating NAFLD and should be initiated as early as possible and continued as long as necessary. Full article
(This article belongs to the Special Issue Fatty Liver Syndrome)
Show Figures

Figure 1

Back to TopTop